Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Treasury Shares: 2014-2024

Historic Treasury Shares for Amicus Therapeutics (FOLD) over the last 10 years, with Dec 2024 value amounting to $8.3 million.

  • Amicus Therapeutics' Treasury Shares fell 99.92% to $7,390 in Q3 2025 from the same period last year, while for Sep 2025 it was $7,390, marking a year-over-year decrease of 99.92%. This contributed to the annual value of $8.3 million for FY2024, which is 17.50% down from last year.
  • Per Amicus Therapeutics' latest filing, its Treasury Shares stood at $8.3 million for FY2024, which was down 17.50% from $10.0 million recorded in FY2023.
  • Amicus Therapeutics' 5-year Treasury Shares high stood at $10.0 million for FY2023, and its period low was $7.1 million during FY2020.
  • Its 3-year average for Treasury Shares is $9.3 million, with a median of $9.7 million in 2022.
  • In the last 5 years, Amicus Therapeutics' Treasury Shares surged by 32.37% in 2022 and then dropped by 17.50% in 2024.
  • Amicus Therapeutics' Treasury Shares (Yearly) stood at $7.1 million in 2020, then grew by 3.69% to $7.3 million in 2021, then skyrocketed by 32.37% to $9.7 million in 2022, then increased by 3.25% to $10.0 million in 2023, then fell by 17.50% to $8.3 million in 2024.